
Balto Pharmaceuticals: Innovating in cancer drug research and development.
Founded with the mission to innovate in cancer drug research and development, Balto Pharmaceuticals focuses on discovering and developing small molecule inhibitors and degraders of protein-protein interactions (PPIs) for cancer and other diseases. Utilizing their proprietary PPI disruption and degradation (PP2D) platform, Balto has identified first-in-class small molecules that target and degrade critical drivers in cancer, offering a novel approach distinct from traditional PROTACs.
Balto Pharmaceuticals has attracted notable investors and affiliations within the biotech industry, contributing to its rapid advancements. The company's key achievements include the successful identification of unique small molecule PPI inhibitors through their PP2D platform, showcasing significant potential in preclinical studies. Balto's innovative approach has positioned it as a promising player in the oncology drug development sector, with the potential to significantly impact cancer treatment paradigms.
Balto Pharmaceuticals' most recent funding round was for $2M (USD) in September 2023.
As of Sep 13, 2023, Balto Pharmaceuticals has disclosed funding of $2M (USD).

Innovo Therapeutics

Ambagon Therapeutics
ambagontx.com
Dual Therapeutics

Onchilles Pharma

Bantam Pharmaceutical
bantampharma.com

Telo Therapeutics

Camino Pharma
caminopharma.com
Advenchen Laboratories
advenchen.com

Pharmatrophix
pharmatrophix.com

NiKang Therapeutics
nikangtx.com

Nexo Therapeutics
nexotx.com

Cage Pharma
cagephar.ma

Neomorph
neomorph.com

PNP Therapeutics

Differentiated Therapeutics
dxtherapeutics.com

Fog Pharmaceuticals
fogpharma.com

Atavistik Bio
atavistikbio.com
BioNumerik Pharmaceuticals

Traws Pharma
trawspharma.com

Synnovation Therapeutics
synnovationtx.com